TGTX Earnings & Financial Statements
TG Therapeutics, Inc.
$54.90
+$1.56(+2.92%)
49
Overall
50
Value
36
Tech
63
Quality
Market Cap
$8.16B
Volume
759.85K
52W Range
$26.76 - $59.30
Target Price
$63.00
TGTX earnings and financial statements: TG Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TGTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $616.29M | $329.00M | $233.66M | $2.79M | $6.69M |
| Cost of revenue | $100.71M | $38.49M | $14.13M | $265.0K | - |
| Operating income | $123.32M | $41.93M | $20.63M | -$192.84M | -$344.77M |
| EBITDA | $137.14M | $53.59M | $30.23M | -$183.28M | -$413.47M |
| Net income | $447.18M | $23.38M | $12.67M | -$198.34M | -$348.10M |
| EPS (diluted) | $2.77 | $0.15 | $0.09 | $-1.46 | $-2.63 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.06B | $577.69M | $329.59M | $193.57M | $379.63M |
| Total liabilities | $415.23M | $355.33M | $169.09M | $134.99M | $142.48M |
| Shareholders’ equity | $648.02M | $222.36M | $160.50M | $58.59M | $237.15M |
| Cash and equivalents | $79.15M | $179.89M | $92.93M | $102.30M | $298.89M |
| Long-term debt | $252.67M | $252.56M | $109.35M | $81.48M | $76.64M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$24.77M | -$40.52M | -$31.41M | -$176.17M | -$295.63M |
| Capital expenditure | -$214.0K | -$45.0K | - | -$14.0K | -$401.0K |
| Free cash flow | -$24.99M | -$40.56M | -$31.41M | -$176.18M | -$296.04M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TGTX | $54.90 | +2.9% | 759.85K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |